ClinicalTrials.gg
CompletedNCT06869408CAP-ICUpdated Jul 31, 2025

Observational Study on the Patient's Ability to Use a Digital Platform in Heart Failure

An observational study in Heart Failure, sponsored by Persei Vivarium. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Persei Vivarium · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.

Enrollment
78th of 78
6 · median 500
Started
2025
with 30 others
Observational
78 of 342
18 open now
Registered
299th of 342
by date

Among the 342 studies in Heart Failure with a site in Spain, this one is the 78th largest by enrollment of the 78 observational ones that give a count, is one of 31 that started in 2025, is one of 78 observational ones, and was the 299th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

71 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

Heart Failure has a global prevalence of 1 to 3% in the adult population with an incidence of 1 to 20 cases per 1,000 people. Furthermore, HF is often associated with a number of comorbidities (anaemia, arrhythmias, depression, hyperuricemia, coronary heart disease etc.), which greatly deteriorates the patient's quality of life.

Despite the development of specific drugs, HF has a very high mortality rate, and it is the first cause of unscheduled income. An increase of 50% of these incomes is expected in the next 25 years.

In this context, the use of digital tools/platforms that allow remote monitoring of patients and that facilitate telemedicine have shown potential to improve treatment adherence and facilitate continued therapeutic education, improving clinical results with savings in time and associated costs.

This study focuses on studying the ability of heart failure patients with reduced ejection fraction (EF≤40%) to use a digital platform through an application installed on the patient's smartphone.

Read the detailed description

This is an observational, prospective, single-center study. The protocol and informed consent document have been reviewed and approved by the Ethical Committee and the study will be performed in accordance with the Declaration of Helsinki

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • Caaring
  • DTx
  • real-world data
  • Digital Health
  • Remote patient monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with heart failure with reduced ejection fraction (EF≤40%)from Hospital Universitario Son Llatzer who met the inclusion criteria and sign the informed consent will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older
  • is obtained from the patient
  • Patients diagnosed with heart failure with reduced (EF≤40%)
  • Patients who extensively use a smartphone.

Exclusion criteria

Exclusion Criteria:

  • Patients who will not be able to commit to carrying out the follow-ups or do not have adequate technological skills.
  • Patients with inability to give adequately the .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Patients' ability to report data through a digital platform: Clinical situation

    Percentage of patients with at least 80% of the data completed per form: clinical situation.

    Time frame: Day 0, every 3 days up to week 12

  2. Patients' ability to report data through a digital platform: Treatment and adherence

    Percentage of patients with at least 80% of the data completed per form: treatment and adherence.

    Time frame: Day 0, and weekly up to week 12

  3. Patients' ability to report data through a digital platform: Quality of Life

    Percentage of patients with at least 80% of the data completed of the quality life questionnaire WHOQOL (World Health Organization Quality Of Life)

    Time frame: Day 0, Week 4 and Week 12

  4. Patients' ability to report data through a digital platform: Mediterranean Diet Adherence

    Percentage of patients with at least 80% of the data completed by MEDAS (Mediterranean Diet Adherence Screener) questionnaire

    Time frame: Day 0, Week 4 and Week 12

  5. Patients' ability to report data through a digital platform: European Heart Failure Self-Care Behaviour Scale

    Percentage of patients with at least 80% of the data completed by EHFScB (European Heart Failure Self-Care Behaviour Scale) scale

    Time frame: Day 0, Week 4 and Week 12

  6. Patients' ability to report data through a digital platform: Liquid Consumption Questionnaire

    Percentage of patients with at least 80% of the data completed by Liquid Consumption Questionnaire

    Time frame: Day 0, Week 4 and Week 12

  7. Patient participation rate

    Patient participation rate defined as the ratio between the questionnaries requested and completed

    Time frame: Week 12

  8. Percentage of patients with at least 80% of data completed.

    Percentage of patients with at least 80% of data completed in the application

    Time frame: Week 12

  9. Percentage of patients with 100% of data completed.

    Percentage of patients with 100% of data completed in the application.

    Time frame: Week 12

Secondary outcomes

  1. Change in the use of health resources

    Change in patient´s use of health resources scores at basal monthly and at the end of the study compared to baseline: Number of visits to specialists (e.g. cardiology, primary care, etc.), number of emergency room visits, or number of hospital readmissions. The changes will be measured through a specific form created for this purpose.

    Time frame: Day 0 and Mothly up to 3 months

  2. Changes in the patient's quality of life scale: WHOQOL

    Changes in patient's quality of life scale WHOQOL (World Health Organization Quality of Life) scores at week 4 and at the end of the study compared to baseline. Values: 0-100, a higher score reflects a better health-related quality of life.

    Time frame: Day 0, week 4 and week 12]

  3. Changes in the patient's MEDAS scale: Adherence to Mediterranean Diet

    Changes in patient's scale MEDAS (Mediterranean Diet Adherence Screener) scores at week 4 and at the end of the study compared to baseline. Values: 0-14, a higher score reflects a better the adherence to the Mediterranean Diet.

    Time frame: Day 0, week 4 and week 12

  4. Changes in the patient's in EHFScB: European Heart Failure Self-Care Behaviour Scale

    Changes in patient's EHFScB scale (European Heart Failure Self-Care Behaviour scale) scores at week 4 and at the end of the study compared to baseline. Values: 0-100, a higher score reflects a better Self-Care Behaviour in the standardized score.

    Time frame: Day 0, week 4 and week 12

  5. Changes in the patient's in Liquid Consumption

    Changes in patient's Liquid Consumption Questionnaire. The changes will be measured through a specific form created for this purpose

    Time frame: Day 0, week 4 and week 12

  6. Changes in the patient's: Adherence to treatment

    Changes in patient's Adherence to treatment measured by patient self-report. The questionnaire ask for treatments taken or forgotten. Changes will be measured through a specific form created for this purpose

    Time frame: Day 0, Weekly up to Week 12

  7. Changes in the patient's Clinical Data

    Changes in patient's Clinical data (symptoms related to heart failure) measured through a specific form created for this purpose.

    Time frame: Day 0, every 3 days up to Week 12

07

Study locations

1 site
  • Hospital Universitario Son Llatzer
    Palma de Mallorca, Balearic Islands 07198, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jun 2025, 4 months.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's 4 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 11, 2025
StartActual
Feb 24, 2025
Primary completionActual
Jun 25, 2025
CompletionActual
Jun 25, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06869408
Lead sponsor
Persei Vivarium
Collaborators
Effice Servicios Para la Investigacion S.L.
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Feb 24, 2025
Primary completion
Jun 25, 2025
Completion
Jun 25, 2025
Last update
Jul 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion